Does MannKind Have Enough Funds to Support the Afrezza Launch? 3Q Earnings Disaster Leaves Questions


It was a bad day to be a MannKind Corporation (NASDAQ:MNKD) investor yesterday after the biotech stock took an around 8% beating in the market on back of a dismal third quarter showing for diabetes drug Afrezza. Maxim analyst Jason Kolbert is shaking his head in frustration, relieved he recently ran to the sidelines.

Story Continues